Financials data is unavailable for this security.
View more
Year on year ASKA Pharmaceutical Holdings Co Ltd grew revenues 3.94% from 60.46bn to 62.84bn while net income improved 78.01% from 4.24bn to 7.55bn.
Gross margin | 49.66% |
---|---|
Net profit margin | 11.70% |
Operating margin | 10.37% |
Return on assets | 8.38% |
---|---|
Return on equity | 12.30% |
Return on investment | 10.69% |
More ▼
Cash flow in JPYView more
In 2024, ASKA Pharmaceutical Holdings Co Ltd did not generate a significant amount of cash. However, Cash Flow from Investing totalled 1.71bn, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 1.49bn in cash from operations while cash used for financing totalled 3.94bn.
Cash flow per share | 348.58 |
---|---|
Price/Cash flow per share | 6.66 |
Book value per share | 2,235.47 |
---|---|
Tangible book value per share | 2,115.35 |
More ▼
Balance sheet in JPYView more
Current ratio | 2.66 |
---|---|
Quick ratio | 1.61 |
Total debt/total equity | 0.1305 |
---|---|
Total debt/total capital | 0.1154 |
More ▼
Growth rates in JPY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 150.00% and 77.57%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked above the industry average relative to its peers.
Div yield(5 year avg) | 1.12% |
---|---|
Div growth rate (5 year) | 23.36% |
Payout ratio (TTM) | 15.32% |
EPS growth(5 years) | 33.95 |
---|---|
EPS (TTM) vs TTM 1 year ago | 69.80 |
More ▼